Zobrazeno 1 - 10
of 44
pro vyhledávání: '"V. Meresse"'
Autor:
Anne Mathieu-Boué, Pierre Demolis, Jean-François Bergmann, M. Aoustin, C. Atlani, F. Bassompierre, R. Benamouzig, M.-J. Bonavita, L. Borella, F. Calvo, C. Caulin, D. Cellier, M. Dahan, V. Daura, F. De Beels, N. De Vernejoul, V. Diebolt, N. Dumarcet, I. Durand Zaleski, E. Fery Lemonnier, J. Genève, I. Giri, D. Golinelli, C. Labreveux, J.-F. Latour, D. Maraninchi, V. Meresse, L. Mignot, D. Morlet, S. Pépin, P. Ravaud, C. Riché, A. Rouleau, P. Tilleul, P. Viens
Publikováno v:
Therapie. 61(4)
Drugs used in oncology represent more than half of the innovative and costly drugs which are not covered by a Group Homogene de Soins (DRG type classification) within the context of the case-mix based payment system (termed T2A). For these drugs, goo
Autor:
Anne Mathieu-Boué, Pierre Demolis, Jean-François Bergmann, M. Aoustin, C. Atlani, F. Bassompierre, R. Benamouzig, M.-J. Bonavita, L. Borella, F. Calvo, C. Caulin, D. Cellier, M. Dahan, V. Daura, F. De Beels, N. De Vernejoul, V. Diebolt, N. Dumarcet, I. Durand Zaleski, E. Fery Lemonnier, J. Genève, I. Giri, D. Golinelli, C. Labreveux, J.-F. Latour, D. Maraninchi, V. Meresse, L. Mignot, D. Morlet, S. Pépin, P. Ravaud, C. Riché, A. Rouleau, P. Tilleul, P. Viens
Publikováno v:
Therapies. 61:305-308
Les medicaments utilises en cancerologie representent plus de la moitie des medicaments innovants et couteux pris en charge hors d'un groupe homogene de soins dans le cadre de la tarification a l'activite. Pour ces medicaments, des referentiels de bo
Autor:
Jayesh Desai, F. Su, Rodrigo Dienstmann, Jonathan Cebon, Stefan Evers, W. Zhang, V. Meresse, J. Tabernero, Ulrik Lassen, Michael P. Brown
Publikováno v:
European Journal of Cancer. 48:177-178
Publikováno v:
British journal of haematology. 100(3)
Neutrophils from 13 children who received G-CSF for the collection of peripheral blood progenitors while they were in haematological steady state were studied at various times after G-CSF injection for Fc gammaR expression (Fc gammaRI or CD64, Fc gam
Publikováno v:
Bone marrow transplantation. 16(6)
We investigated the long-term pulmonary sequelae of 38 children surviving 3 to 11.5 years (median 7 years) after high-dose chemotherapy (HDC) and autologous bone marrow transplantation (ABMT) without TBI. This cross-sectional study included patients
Publikováno v:
Bone marrow transplantation. 16(4)
Despite intensification of treatment with high-dose chemotherapy (HDC) and autologous bone marrow transplantation (AMBT), the prognosis of poorly responding metastatic neuroblastoma remains bad. Recombinant IL-2 (rIL-2) was used after ABMT to enhance
Autor:
L, Brugières, M, Gardes, C, Moutou, A, Chompret, V, Meresse, A, Martin, N, Poisson, F, Flamant, C, Bonaïti-Pellié, J, Lemerle
Publikováno v:
Cancer research. 53(3)
We have undertaken a routine investigation of the p53 status for all the children treated at our institution either affected by multiple tumors or whose family displays at least one second degree relative or less, affected by cancer before the age of
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Martine Escoffre-Barbe, V. Meresse, V. Dubruille, Bruno Varet, Mahon Fx, François Guilhot, Joelle Guilhot, P. Berthaud, Claude Preudhomme, Frédéric Maloisel
Publikováno v:
ResearcherID
6589 Background: Despite impressive results achieved with IM 400 mg/day alone, only a minority of pts reached a complete molecular remission at 12-month. Higher dose of IM or its combination with other therapies might improve molecular remission. Des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03b34a0f493edc6f12e5bcec3322ac98
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000239009402302&KeyUID=WOS:000239009402302
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000239009402302&KeyUID=WOS:000239009402302